Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Chungcheongbul-do
-
Daejeon, Chungcheongbul-do, Korea, Republic of, 301-721
- Chungnam national university hospital,clinical trial center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male, Age 20 to 45
- Subject must be willing and able to provide written informed consent to the study.
Exclusion Criteria:
- History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.
- History of any significant gastrointestinal system and surgery of gastrointestinal.
- History of any significant hypersensitivity to amlodipine, candesartan, aspirin, antibiotic.
- Over 10 tobaccos a day.
- Other condition which in the opinion of the investigator preclude endrollment into the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: PartA: Candesartan, Candesartan + Amolodipine
Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
|
|
|
Active Comparator: PartB: Amlodipine, Amlodipine+Candesartan
Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part A : AUC, Cmax of Candesartan
Time Frame: Over a 24-hour sampling period
|
Over a 24-hour sampling period
|
|
Par B : AUC, Cmax of Amlodipine
Time Frame: Over a 24-hour sampling period
|
Over a 24-hour sampling period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PartA: Cmin, tmax, CL/F of Candesartan
Time Frame: Over a 24-hour sampling period
|
Over a 24-hour sampling period
|
|
PartB: Cmin, tmax, CL/F of Amlodipine
Time Frame: Over a 24-hour sampling period
|
Over a 24-hour sampling period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jang Hee Hong, Associate Professor, Chungnam national university hospital, Clinical trial center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension
- Calcium-Regulating Hormones and Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Calcium Channel Blockers
- Vasodilator Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Candesartan
- Candesartan cilexetil
Other Study ID Numbers
Other Study ID Numbers
- HAMCAO12I_1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.